Crisci Elisa, Bárcena Juan, Montoya María
Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Vet Immunol Immunopathol. 2012 Aug 15;148(3-4):211-25. doi: 10.1016/j.vetimm.2012.04.026. Epub 2012 Jun 1.
Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology.
疫苗接种仍然是保护动物免受传染病侵害的主要方法。直到最近,所有获批的疫苗都是使用传统技术研发的。然而,亚单位疫苗正受到兽医疫苗学领域研究人员的关注,其中病毒样颗粒(VLP)是最具吸引力的方法之一。VLP是纳米级的坚固蛋白笼,模仿天然病毒粒子的整体结构,但缺乏病毒基因组。它们通常在抗原性上与所衍生的病毒无法区分,并且在安全性方面具有重要优势。VLP可以刺激强烈的体液免疫和细胞免疫反应,并且已被证明具有自我佐剂能力。除了适合作为其所衍生同源病毒的疫苗外,VLP还可以用作多聚体呈现外源抗原的载体。因此,VLP作为候选疫苗已显示出显著的有效性。在这里,我们综述了VLP作为兽医领域疫苗技术的现状,并讨论了该技术的潜在优势和挑战。